Precipio is trying to prove that a two-lab hematology franchise can fund its own kit business and stop living on the capital markets. Quarterly sales cleared $7 million for the first time, and management used that print to argue the at-the-market financing era is over. The investment debate is whether that cash build is a durable operating state or a one-quarter cocktail of delayed kit shipments, payroll-tax credits, and option-expense add-backs.
Pathology still does almost all the economic work. Service sales of $6.1 million barely moved sequentially, while product sales printed a record $0.9 million. Adjusted earnings before interest, taxes, depreciation, and amortization flipped to $0.4 million after a first-quarter loss, but reported results still lost money because option expense roughly doubled. Cash ended above $3 million with no new financing, which is the operational claim bulls want to underwrite. The same mid-year filing still recites substantial doubt about remaining a going concern.
Diagnostic cases in the June quarter rose to 4652. That compares with 3692 a year earlier. The commercial team hired in January is walking more than 25 qualified kit accounts through hospital information-technology and validation queues. The question the second half answers is whether those accounts go live fast enough for product sales to keep compounding, or whether the pathology engine stalls under payer cuts while the going-concern paragraph stays in the footnotes.